Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.
Kishan AU, Sun Y, Hartman H, Pisansky TM, Bolla M, Neven A, Steigler A, Denham JW, Feng FY, Zapatero A, Armstrong JG, Nabid A, Carrier N, Souhami L, Dunne MT, Efstathiou JA, Sandler HM, Guerrero A, Joseph D, Maingon P, de Reijke TM, Maldonado X, Ma TM, Romero T, Wang X, Rettig MB, Reiter RE, Zaorsky NG, Steinberg ML, Nickols NG, Jia AY, Garcia JA, Spratt DE; MARCAP Consortium group. Kishan AU, et al. Among authors: maingon p. Lancet Oncol. 2022 Feb;23(2):304-316. doi: 10.1016/S1470-2045(21)00705-1. Epub 2022 Jan 17. Lancet Oncol. 2022. PMID: 35051385
Guidelines for primary radiotherapy of patients with prostate cancer.
Boehmer D, Maingon P, Poortmans P, Baron MH, Miralbell R, Remouchamps V, Scrase C, Bossi A, Bolla M; EORTC radiation oncology group. Boehmer D, et al. Among authors: maingon p. Radiother Oncol. 2006 Jun;79(3):259-69. doi: 10.1016/j.radonc.2006.05.012. Epub 2006 Jun 22. Radiother Oncol. 2006. PMID: 16797094
Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group.
Poortmans P, Bossi A, Vandeputte K, Bosset M, Miralbell R, Maingon P, Boehmer D, Budiharto T, Symon Z, van den Bergh AC, Scrase C, Van Poppel H, Bolla M; EORTC Radiation Oncology Group. Poortmans P, et al. Among authors: maingon p. Radiother Oncol. 2007 Aug;84(2):121-7. doi: 10.1016/j.radonc.2007.07.017. Epub 2007 Aug 13. Radiother Oncol. 2007. PMID: 17706307
Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: dummy run and individual case review.
Matzinger O, Poortmans P, Giraud JY, Maingon P, Budiharto T, van den Bergh AC, Davis JB, Musat E, Ataman F, Huyskens DP, Gulyban A, Bolla M; EORTC Radiation Oncology Group. Matzinger O, et al. Among authors: maingon p. Radiother Oncol. 2009 Mar;90(3):285-90. doi: 10.1016/j.radonc.2008.10.022. Epub 2008 Nov 27. Radiother Oncol. 2009. PMID: 19038468 Clinical Trial.
Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: preliminary results of a multicentre phase II trial.
Bolla M, Hannoun-Levi JM, Ferrero JM, Maingon P, Buffet-Miny J, Bougnoux A, Bauer J, Descotes JL, Fourneret P, Jover F, Colonna M. Bolla M, et al. Among authors: maingon p. Radiother Oncol. 2010 Nov;97(2):312-7. doi: 10.1016/j.radonc.2010.08.012. Epub 2010 Sep 16. Radiother Oncol. 2010. PMID: 20846737 Clinical Trial.
Radiotherapy and androgen deprivation for prostate cancer.
Créhange G, Bolla M, Maingon P. Créhange G, et al. Among authors: maingon p. N Engl J Med. 2011 Oct 6;365(14):1354; author reply 1354-5. doi: 10.1056/NEJMc1109225. N Engl J Med. 2011. PMID: 21991967 No abstract available.
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, Bardet E, Beny A, Ollier JC, Bolla M, Marchal D, Van Laethem JL, Klein V, Giralt J, Clavère P, Glanzmann C, Cellier P, Collette L; EORTC Radiation Oncology Group. Bosset JF, et al. Among authors: maingon p. Lancet Oncol. 2014 Feb;15(2):184-90. doi: 10.1016/S1470-2045(13)70599-0. Epub 2014 Jan 17. Lancet Oncol. 2014. PMID: 24440473 Clinical Trial.
Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.
Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, Schinagl D, Oei B, Rodenhuis C, Horiot JC, Struikmans H, Van Limbergen E, Kirova Y, Elkhuizen P, Bongartz R, Miralbell R, Morgan D, Dubois JB, Remouchamps V, Mirimanoff RO, Collette S, Collette L; European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Bartelink H, et al. Among authors: maingon p. Lancet Oncol. 2015 Jan;16(1):47-56. doi: 10.1016/S1470-2045(14)71156-8. Epub 2014 Dec 9. Lancet Oncol. 2015. PMID: 25500422 Clinical Trial.
Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991.
Bolla M, Maingon P, Carrie C, Villa S, Kitsios P, Poortmans PM, Sundar S, van der Steen-Banasik EM, Armstrong J, Bosset JF, Herrera FG, Pieters B, Slot A, Bahl A, Ben-Yosef R, Boehmer D, Scrase C, Renard L, Shash E, Coens C, van den Bergh AC, Collette L. Bolla M, et al. Among authors: maingon p. J Clin Oncol. 2016 May 20;34(15):1748-56. doi: 10.1200/JCO.2015.64.8055. Epub 2016 Mar 14. J Clin Oncol. 2016. PMID: 26976418 Clinical Trial.
296 results